Versant and Novartis build 'Chinook 2.0' for RNA therapies in kidney diseases
Five years to the day after launching Chinook Therapeutics, Versant Ventures is back with a second generation of that kidney disease biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.